Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Cipla, Siga Technologie in pact for innovation in novel antibacterial drugs » 08:07
03/23/21
03/23
08:07
03/23/21
08:07
SIGA

Siga Technologies

$6.74 /

-0.07 (-1.03%)

Cipla Therapeutic and…

Cipla Therapeutic and SIGA Technologies announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. The World Health Organization has declared that anti-microbial resistance one of the top 10 global public health threats facing humanity2 which puts at risk the effective prevention and treatment of a wide range of infections. According to the AMR Industry Alliance, a global AMR private sector coalition, AMR is the ability of a microorganism to stop an antimicrobial such as antibiotics, antivirals and from working against it. It is an increasingly significant threat to global public health which is present in every country around the world and infections caused by drug-resistant bacteria can cause death. "The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority, a U.S. Department of Health and Human Services department, with solutions for its biothreat and public health needs," said Garrett Ingram, CEO of Cipla Therapeutics and added "AMR is a global priority for Cipla and our continued investment in this area along with SIGA's drug development and US experience creates a unique and strong partnership." "We are thrilled to have teamed up with Cipla to tackle the very important public health challenge of AMR," said Phil Gomez, CEO of SIGA. "Our longtime partner BARDA has recognized this as a critical issue, for not only public health, but biothreats as well. With our drug development expertise under the animal rule and government contracting expertise, and Cipla's novel antibiotic products and extensive manufacturing capabilities, we are confident that together we are ideally-suited to provide innovative solutions to BARDA and other government customers."

ShowHide Related Items >><<
SIGA Siga Technologies
$6.74 /

-0.07 (-1.03%)

Over a month ago
Hot Stocks
Siga Technologies: Meridian Medical to purchase up to $33M of oral TPOXX » 16:51
01/13/21
01/13
16:51
01/13/21
16:51
SIGA

Siga Technologies

$7.29 /

-0.14 (-1.88%)

, PFE

Pfizer

$36.87 /

-0.3 (-0.81%)

SIGA Technologies (SIGA)…

SIGA Technologies (SIGA) announced that the Public Health Agency of Canada has awarded a contract to Meridian Medical Technologies, a Pfizer (PFE) company, for the purchase up to approximately $33M of oral TPOXX within five years. The contract specifies firm commitments for the purchase of approximately $3.4M of oral TPOXX by March 31, 2021 and a cumulative purchase of approximately $17.2M of oral TPOXX by March 31, 2023; the remaining courses under the Contract are scheduled to be purchased after March 31, 2023 and are subject to option exercise by PHAC. The Contract award follows, but is separate and incremental to, the issuance in April, 2020 of a contract by the Canadian Department of National Defence for the delivery of up to approximately $14M of oral TPOXX. As with all international sales of TPOXX, Meridian is the counterparty to the contract and SIGA will be responsible for the manufacture and delivery of product. SIGA anticipates Canadian regulatory approval in late 2021 or early 2022.

ShowHide Related Items >><<
SIGA Siga Technologies
$7.29 /

-0.14 (-1.88%)

PFE Pfizer
$36.87 /

-0.3 (-0.81%)

SIGA Siga Technologies
$7.29 /

-0.14 (-1.88%)

PFE Pfizer
$36.87 /

-0.3 (-0.81%)

01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/29/20 Citi
Citi boosts Myovant target to $30 on 'smart deal' with Pfizer
12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
PFE Pfizer
$36.87 /

-0.3 (-0.81%)

PFE Pfizer
$36.87 /

-0.3 (-0.81%)

PFE Pfizer
$36.87 /

-0.3 (-0.81%)

PFE Pfizer
$36.87 /

-0.3 (-0.81%)

Over a quarter ago
Hot Stocks
SIGA announces PHAC intent to purchase up to 33,300 courses of oral TPOXX » 07:34
10/08/20
10/08
07:34
10/08/20
07:34
SIGA

Siga Technologies

$7.06 /

+0.06 (+0.86%)

SIGA Technologies…

SIGA Technologies announced that the Public Health Agency of Canada has issued an advanced contract award notice, indicating that the PHAC intends to purchase up to 33,300 courses of oral TPOXX within five years as specified in the ACAN, with 3,700 courses to be delivered by March 31, 2021; a cumulative total of 18,500 courses to be delivered by March 31, 2023; and an additional 14,800 courses to be delivered after March 31, 2023, subject to option exercise. The ACAN is required to remain open for at least 15 days, during which time a potential alternative supplier may submit a competing Statement of Capabilities. This ACAN follows, but is separate and incremental to, the issuance in April, 2020 of a contract by the Canadian Department of National Defence for the delivery of up to 15,325 courses of oral TPOXX. The value of courses to be sold to Canada will be disclosed upon any final award by the Canadian government. In any contract issued by Canada, Meridian Medical Technologies, will be the counterparty to the contract and SIGA will be responsible for the manufacture and delivery of product. SIGA was also previously awarded separate funding by the Canadian authorities to support submission of an application for marketing authorization of oral TPOXX to Health Canada, which is targeted to be submitted by the end of 2020. SIGA anticipates approval in 2021.

ShowHide Related Items >><<
SIGA Siga Technologies
$7.06 /

+0.06 (+0.86%)

Conference/Events
Siga Technologies to host business news update conference call » 16:25
08/06/20
08/06
16:25
08/06/20
16:25
SIGA

Siga Technologies

$6.49 /

-0.23 (-3.42%)

Dr. Gomez, CEO and CFO…

Dr. Gomez, CEO and CFO Luckshire hold a business news update conference call on August 6 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
SIGA Siga Technologies
$6.49 /

-0.23 (-3.42%)

Conference/Events
Siga Technologies to host business news update conference call » 10:42
08/06/20
08/06
10:42
08/06/20
10:42
SIGA

Siga Technologies

$6.72 /

+ (+0.00%)

Dr. Gomez, CEO and CFO…

Dr. Gomez, CEO and CFO Luckshire hold a business news update conference call on August 6 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
SIGA Siga Technologies
$6.72 /

+ (+0.00%)

Hot Stocks
Siga Technologies files MAA for oral tecovirimat » 08:17
07/30/20
07/30
08:17
07/30/20
08:17
SIGA

Siga Technologies

$6.65 /

-0.09 (-1.34%)

SIGA Technologies…

SIGA Technologies announced that it has filed a Marketing Authorisation Application with the European Medicines Agency for oral tecovirimat, the same formulation that was approved by the U.S. Food and Drug Administration in July 2018 under the name TPOXX. The MAA was filed under the centralized application process, which, upon approval, and will enable sales and marketing of oral tecovirimat in all EU member states, as well as Norway, Iceland, and Liechtenstein. SIGA has filed its application for oral tecovirimat seeking a broader label indication covering the treatment of smallpox, monkeypox, cowpox, and complications from Vaccinia infection. SIGA is targeting approval for the second half of 2021. On July 13, 2018, the FDA approved oral TPOXX for the treatment of smallpox to mitigate the impact of a potential outbreak or bioterror attack. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for this indication, and was developed through funding and collaboration with the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services, as well as early stage development supported by the National Institutes of Health, U.S. Centers for Disease Control and Prevention, and Department of Defense. The US currently maintains a stockpile of 1.7 million courses of TPOXX. In June 2019, SIGA entered into an international promotion agreement with Meridian. Under the agreement, Meridian will promote the sale of oral tecovirimat for the treatment of smallpox in all international markets, except the United States and South Korea. SIGA will continue to own all rights to the product and its related intellectual property. On June 1, 2020, SIGA announced its first international sale with 2,500 courses delivered to the Canadian Department of National Defence.

ShowHide Related Items >><<
SIGA Siga Technologies
$6.65 /

-0.09 (-1.34%)

Hot Stocks
Siga Technologies announces $32M in Tpoxx deliveries to HHS » 16:08
06/25/20
06/25
16:08
06/25/20
16:08
SIGA

Siga Technologies

$6.17 /

+0.21 (+3.52%)

Siga Technologies…

Siga Technologies announced the deliveries of oral Tpoxx to the U.S. Department of Health and Human Services, or HHS. These deliveries, valued at approximately $32M, are the initial deliveries of the contract option exercises announced in April. The previously-announced option exercises under the 2018 contract with the Biomedical Advanced Research and Development Authority, or BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at HHS, are worth a total of approximately $101.3M for the procurement of oral Tpoxx. Deliveries of oral Tpoxx to maintain national preparedness under these option exercises are expected to be completed by April 2021. SIGA's full 19C BARDA Contract has up to approximately $414M of procurement-related options remaining for future exercise.

ShowHide Related Items >><<
SIGA Siga Technologies
$6.17 /

+0.21 (+3.52%)

Hot Stocks
Siga Technologies says DoD increases funding to develop PEP indication for TPOXX » 07:39
06/15/20
06/15
07:39
06/15/20
07:39
SIGA

Siga Technologies

$5.62 /

-0.04 (-0.71%)

SIGA Technologies…

SIGA Technologies announced that the United States Department of Defense, via the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense's Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical, has increased research and development funding to approximately $23M in connection with the DoD contract to support work necessary to gain a potential label expansion from the U.S. Food and Drug Administration for TPOXX for Post-Exposure Prophylaxis in addition to the current approved labeling for the treatment of smallpox. The use of TPOXX for PEP could provide significant potential benefit in the event of a smallpox pandemic or outbreak. While vaccines would play an important role in containing the spread of smallpox, they are only effective if administered prior to infection or no later than four days after infection. However, symptoms of smallpox do not typically appear until approximately 14 days post-infection, and there is currently no diagnostic test to determine infection prior to symptom onset. Given the uncertainty of an individual's infection status in that two-week period, and the highly contagious nature of smallpox, the administration of a vaccine in combination with TPOXX could be an important strategy for reducing morbidity and mortality in a smallpox outbreak. Dosing of TPOXX in the PEP indication is expected to be 28 days rather than the 14-day dosing currently recommended for its use in treating patients with active smallpox infections. This would increase the amount of TPOXX used for each exposed person compared with each infected person.

ShowHide Related Items >><<
SIGA Siga Technologies
$5.62 /

-0.04 (-0.71%)

Hot Stocks
Siga Technologies announces international delivery of oral TPOXX » 09:16
06/01/20
06/01
09:16
06/01/20
09:16
SIGA

Siga Technologies

$6.00 /

-0.09 (-1.48%)

SIGA Technologies…

SIGA Technologies announced its first international delivery of TPOXX, with 2,500 courses delivered to the Canadian Department of National Defence. On April 3, 2020, the Company previously announced that the CDND is expected to purchase up to 15,325 courses of oral TPOXX over four years for a total value of $14.3 million. Remaining purchases of 12,825 courses, at the option of the CDND, are expected to occur after regulatory approval of oral TPOXX by Health Canada. Meridian Medical Technologie, SIGA's partner for international promotion of TPOXX, is the counterparty to the Canadian Contract and SIGA is responsible for the manufacture and delivery of oral TPOXX. In addition to the Canadian product delivery, SIGA also expects to make deliveries of oral TPOXX to the U.S. Government this month. As previously disclosed, SIGA expects to deliver $101.3 million of oral TPOXX to the U.S. Government by April 2021, with deliveries starting this month. These deliveries will be in connection with the recent option exercises under its 2018 Biomedical Advanced Research and Development Authority contract. In addition to the options recently exercised, SIGA's full 19C BARDA Contract has up to $414 million of procurement-related options remaining for future exercise.

ShowHide Related Items >><<
SIGA Siga Technologies
$6.00 /

-0.09 (-1.48%)

Conference/Events
Siga Technologies to hold a business news update conference call » 16:25
05/06/20
05/06
16:25
05/06/20
16:25
SIGA

Siga Technologies

$5.82 /

+0.03 (+0.52%)

Conference call to…

Conference call to provide a business update, as well as discuss 1Q reported earnings on May 6 at 4:30 pm. Webcast Link

ShowHide Related Items >><<

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.